IRIS
VIGNERI, PAOLO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 6.248
EU - Europa 3.568
AS - Asia 2.074
SA - Sud America 450
AF - Africa 385
OC - Oceania 6
Continente sconosciuto - Info sul continente non disponibili 5
Totale 12.736
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 6.012
IT - Italia 1.323
SG - Singapore 1.215
IE - Irlanda 766
CN - Cina 653
UA - Ucraina 573
BR - Brasile 419
DE - Germania 257
CI - Costa d'Avorio 241
CA - Canada 226
RU - Federazione Russa 164
SN - Senegal 110
BE - Belgio 100
NL - Olanda 100
SE - Svezia 63
GB - Regno Unito 55
VN - Vietnam 54
CZ - Repubblica Ceca 32
IN - India 31
FI - Finlandia 29
FR - Francia 24
CH - Svizzera 20
NG - Nigeria 18
UZ - Uzbekistan 18
JP - Giappone 16
GR - Grecia 15
IR - Iran 14
AR - Argentina 12
AT - Austria 12
PL - Polonia 11
TR - Turchia 10
IQ - Iraq 9
ES - Italia 8
LB - Libano 8
BD - Bangladesh 7
AE - Emirati Arabi Uniti 6
EC - Ecuador 6
IL - Israele 6
MA - Marocco 6
MX - Messico 6
AU - Australia 5
BG - Bulgaria 5
EU - Europa 4
PK - Pakistan 4
CO - Colombia 3
EG - Egitto 3
OM - Oman 3
PY - Paraguay 3
TN - Tunisia 3
VE - Venezuela 3
AL - Albania 2
AZ - Azerbaigian 2
HK - Hong Kong 2
JO - Giordania 2
KE - Kenya 2
KR - Corea 2
KZ - Kazakistan 2
NI - Nicaragua 2
NO - Norvegia 2
NP - Nepal 2
PE - Perù 2
RO - Romania 2
RS - Serbia 2
AM - Armenia 1
BA - Bosnia-Erzegovina 1
BH - Bahrain 1
BO - Bolivia 1
DZ - Algeria 1
GL - Groenlandia 1
HU - Ungheria 1
ID - Indonesia 1
JM - Giamaica 1
MY - Malesia 1
NZ - Nuova Zelanda 1
PH - Filippine 1
PS - Palestinian Territory 1
PT - Portogallo 1
SA - Arabia Saudita 1
TH - Thailandia 1
UY - Uruguay 1
XK - ???statistics.table.value.countryCode.XK??? 1
ZA - Sudafrica 1
Totale 12.736
Salva come PNG Salva come JPEG
Città #
Santa Clara 1.344
Chandler 840
Dublin 766
Singapore 723
Jacksonville 648
Chicago 501
Catania 353
Boardman 332
Abidjan 241
Cambridge 207
Lawrence 204
Nanjing 200
Andover 194
Toronto 156
Ashburn 137
Grafing 135
Des Moines 112
Dakar 110
San Mateo 101
Civitanova Marche 98
Wilmington 86
Ottawa 55
Rotterdam 53
Nanchang 51
Wingene 50
Palermo 49
Hebei 47
Shenyang 46
Milan 45
Munich 45
Dong Ket 40
Saint Petersburg 38
Bremen 34
Brussels 34
Portland 33
Rome 33
Changsha 31
Jiaxing 30
Council Bluffs 29
Seattle 29
Brno 28
São Paulo 27
Falls Church 26
Tianjin 26
Bari 25
Los Angeles 23
San Giovanni la Punta 23
Moscow 19
Abuja 18
Pune 17
Helsinki 16
Quintano 16
Tokyo 16
Messina 15
Hanoi 14
Houston 14
Jinan 14
Aci Catena 13
Bernareggio 13
Florence 13
Frankfurt Am Main 13
Santa Venerina 13
Augusta 12
Belo Horizonte 12
Lappeenranta 12
Brasília 11
Hangzhou 11
Kunming 11
Leawood 11
Nijmegen 11
Norwalk 11
Rio de Janeiro 11
Woodbridge 11
Ardabil 10
Curitiba 10
Giarre 10
Gioiosa Marea 10
Ningbo 10
Verona 10
Zhengzhou 10
Beijing 9
Izegem 9
Mascalucia 9
Siracusa 9
Guangzhou 8
Liberty Lake 8
Padova 8
Acireale 7
Cosenza 7
Den Haag 7
Fantina 7
Redmond 7
Reggio Emilia 7
Washington 7
Ann Arbor 6
Cesa 6
Hanover 6
Knoxville 6
Paternò 6
Richmond 6
Totale 9.001
Salva come PNG Salva come JPEG
Nome #
Novel mechanisms of tumor promotion by the insulin receptor isoform a in triple-negative breast cancer cells 184
Clinical Implications of Discordant Early Molecular Responses in CML Patients Treated with Imatinib 151
Non ABL-directed inhibitors as alternative treatment strategies for chronic myeloid leukemia 110
Knockout Serum Replacement Promotes Cell Survival by Preventing BIM from Inducing Mitochondrial Cytochrome C Release 106
A Custom DNA-Based NGS Panel for the Molecular Characterization of Patients With Diffuse Gliomas: Diagnostic and Therapeutic Applications 105
Effect of low-dose tungsten on human thyroid stem/precursor cells and their progeny 102
Glioblastoma, IDH-Wild Type With FGFR3-TACC3 Fusion: When Morphology May Reliably Predict the Molecular Profile of a Tumor. A Case Report and Literature Review 100
DDR1 regulates thyroid cancer cell differentiation via IGF-2/IR-A autocrine signaling loop 96
Diagnostic utility of the immunohistochemical expression of serin and arginine rich splicing factor 1 (Srsf1) in the differential diagnosis of adult gliomas 96
High BCR-ABL/GUSISlevels at diagnosis of chronic phase CML are associated with unfavorable responses to standard-dose imatinib 91
Activation of the IGF axis in thyroid cancer: Implications for tumorigenesis and treatment 91
A Case of Non-Irradiated Balloon Cell Melanoma of the Choroid: Expanding the Morphological Spectrum of Primary Uveal Melanomas 90
Biomarkers and prognostic factors for malignant pleural mesothelioma 87
The Q-LAMP Method Represents a Valid and Rapid Alternative for the Detection of the BCR-ABL1 Rearrangement in Philadelphia-Positive Leukemias 87
Anaplastic thyroid cancer in sicily: The role of environmental characteristics. 83
Molecular Alterations in Thyroid Cancer: From Bench to Clinical Practice 82
Concordance between CDKN2A homozygous deletion and MTAP immunohistochemical loss in fluoroedenite-induced pleural mesothelioma: An immunohistochemical and molecular study on a single-institution series 81
BCR-ABL residues interacting with ponatinib are critical to preserve the tumorigenic potential of the oncoprotein 81
BCR-ABL1 doubling-times and halving-times may predict CML response to tyrosine kinase inhibitors 80
BCR-ABL TYROSINE KINASE ACTIVITY MODULATES THE PHOSPHORYLATION, LOCALIZATION AND FUNCTION OF INTERFERON REGULATORY FACTOR 5 (IRF-5) IN CHRONIC MYELOID LEUKEMIA CELLS 78
Chk1 Inhibition Restores Inotuzumab Ozogamicin Citotoxicity in CD22-Positive Cells Expressing Mutant p53 78
Uncommon long-term survival in a patient with chronic myeloid leukemia 77
BCR-Abl tyrosine kinase activity modulates the expression of Interferon Regulatory Factor-5 in CML cells 77
New insights in thyroid cancer and p53 family proteins 77
Altered expression of c-IAP1, survivin, and Smac contributes to chemotherapy resistance in thyroid cancer cells.Cancer Res 76
AKT Inhibitors: New Weapons in the Fight Against Breast Cancer? 76
BCR-ABL tyrosine kinase activity modulates the phosphorylation and the localization of Interferon Regulatory Factor 5 (IRF-5)in Chronic Myeloid Leukemia cells 75
Discoidin domain receptor 1 modulates insulin receptor signaling and biological responses in breast cancer cells 75
Next generation sequencing in a cohort of patients with rare sarcoma histotypes: A single institution experience 75
Unsuccessful dasatinib therapy in a refractory patient with chronic lymphocytic leukemia 74
Computational and Experimental Characterization of Two Nuclear Localization Signals and a Nuclear Export Signal that modulate BCR intracellular localization 74
AN INSERTION IN THE BCR-ABL KINASE DOMAIN CONTRIBUTES TO IMATINIB MESYLATE RESISTANCE 74
Comparative proteomic analysis of insulin receptor isoform A and B signaling 73
DeltaNp73alpha inhibits PTEN expression in thyroid cancer cells 73
Vg9Vd2 T Lymphocytes Efficiently Recognize and Kill Zoledronate-Sensitized, Imatinib-Sensitive, and Imatinib-Resistant Chronic Myelogenous Leukemia Cells 73
BCR-ABL tyrosine kinase activity modulates survivin expression via PI3K/AKT 73
Diagnostic methods and therapeutic options of uveal melanoma with emphasis on MR imaging—Part I: MR imaging with pathologic correlation and technical considerations 73
An Optimized Workflow to Evaluate Estrogen Receptor Gene Mutations in Small Amounts of Cell-Free DNA 73
Suppression of survivin induced by BCR-ABL/JAK2/STAT3 pathway sensitizes imatinib-resistant CML cells to different cytotoxic drugs 72
BCR-ABL Tyrosine Kinase Activity Modulates the Phosphorylation, Localization and Function of Interferon Regulatory Factor 5 (irf-5) in Chronic Myeloid Leukemia (CML) Cells 72
The prognostic and predictive value of ESR1 fusion gene transcripts in primary breast cancer 72
Heavy metals in the volcanic environment and thyroid cancer 71
Early occurrence of a thyroid carcinoma in a patient who developed Graves’ disease after treatment for Hodgkin’s disease 71
Impact of the Breakpoint Region on the Leukemogenic Potential and the TKI Responsiveness of Atypical BCR-ABL1 Transcripts 71
Insulin receptor isoforms differently regulate cell proliferation and apoptosis in the ligand‐occupied and unoccupied state 71
BCR-ABL TYROSINE KINASE ACTIVITY MODULATES THE PHOSPHORYLATION, LOCALIZATION AND BIOLOGICAL FUNCTION OF INTERFERON REGULATORY FACTOR 5 IN CHRONIC MYELOID LEUKEMIA CELLS 70
A population-based study of chronic myeloid leukemia patients treated with imatinib in first line 69
Combined inhibition of bcl2 and bcr-abl1 exercises anti-leukemia activity but does not eradicate the primitive leukemic cells 69
RET/NTRK1 rearrangements in thyroid gland tumors of the papillary carcinoma family: correlation with clinicopathological features 68
c-IAP1, Survivin and Smac contribute to chemotherapy resistance in undifferentiated thyroid cancer cells 68
Hypoxia Induces Imatinib Resistance in CML Cell Lines 68
Mechanistic Translation of Melanoma Genetic Landscape in Enriched Pathways and Oncogenic Protein-Protein Interactions 68
BCR-ABL tyrosine kinase activity modulates Survivin expression in CML cells 67
IRF5 is a target of BCR-ABL kinase activity and reduces CML cell proliferation. 67
Concomitant and feasible treatment with dasatinib and the anti-EGFR antibody cetuximab plus radiotherapy in a CML patient with multiple squamous neoplasias 67
Late Breaking Abstract - Comparison of VATS debulking surgery and HITHOC vs VATS talc pleurodesis alone in malignant pleural mesothelioma: a pilot study 67
Age-related activation of the tyrosine kinase receptor protooncogenes RET and NTRK1 in papillary thyroid carcinoma 66
ENDOMETRIAL STROMAL TUMOR (SARCOMA) WITH LIMITED MIOMETRIAL INFILTRATION: A RARE CASE WITH PELVI-PERITONEAL METASTASES 66
FLAIRectomy in Supramarginal Resection of Glioblastoma Correlates With Clinical Outcome and Survival Analysis: A Prospective, Single Institution, Case Series 66
Several site-specific cancers are increased in the volcanic area in Sicily 65
Mesenchymal Stem Cells (MSC) Regulate Activation of Granulocyte-Like Myeloid Derived Suppressor Cells (G-MDSC) in Chronic Myeloid Leukemia Patients 65
Long-Term Molecular Remission Achieved by Antibody Anti-CD22 and Ponatinib in a Patient Affected by Ph'+ Acute Lymphoblastic Leukemia Relapsed after Second Allogeneic Hematopoietic Stem Cell Transplantation: A Case Report 65
Cerebellar liponeurocytoma: clinical, histopathological and molecular features of a series of three cases, including one recurrent tumor 65
Exclusion of c-Abl from the Nucleus Restrains the p73 Tumor Suppression Function 64
Increased thyroid cancer incidence in volcanic areas: A role of increased heavy metals in the environment? 64
p73 tumor-suppressor activity is impaired in human thyroid cancer 63
The p53-homologue p63 may promote thyroid cancer progression 63
UNA INSERZIONE NEL DOMINIO TIROSIN-CHINASICO DI BCR-ABL POTREBBE CONTRIBUIRE ALLA RESISTENZA AD IMATINIB MESILATO DI PAZIENTI AFFETTI DA LEUCEMIA MIELOIDE CRONICA 63
BCR-ABL modifies the expression and function of the IRF-5 transcription factor 63
INVOLVEMENT OF THE P53 HOMOLOGOUS P73 IN THYROID CANCER PROGRESSION 63
Concentration of Metals and Trace Elements in the Normal Human and Rat Thyroid: Comparison with Muscle and Adipose Tissue and Volcanic Versus Control Areas 63
Adipose stem cell niche reprograms the colorectal cancer stem cell metastatic machinery 63
The PU.1 transcription factor induces cyclin D2 expression in U937 cells 62
Silencing of survivin induced by BCR-ABL/JAK2/STAT3 pathway kills CML cells and sensitizes IM-resistant clones to hydroxyurea 62
Clinical and molecular mechanisms favoring cancer initiation and progression in diabetic patients 62
Detection of an activating mutation of the thyrotropin receptor in a case of an autonomously hyperfunctioning thyroid insular carcinoma 62
Managing chronic myeloid leukemia for treatment-free remission: a proposal from the GIMEMA CML WP 62
Potential Therapeutic Targets for Luminal Androgen Receptor Breast Cancer: What We Know so Far 61
BCR-ABL nuclear entrapment kills human CML cells: ex vivo study on 35 patients with the combination of imatinib mesylate and leptomycin B 61
Histopathologic and mr imaging appearance of spontaneous and radiation-induced necrosis in uveal melanomas: Initial results 61
Additional Genetic Alterations and Clonal Evolution of MPNs with Double Mutations on the MPL Gene: Two Case Reports 60
Prognostic and Therapeutic Roles of the Insulin Growth Factor System in Glioblastoma 60
HMGA1 inhibits the function of p53 family members in thyroid cancer cells 60
Diagnostic methods and therapeutic options of uveal melanoma with emphasis on MR imaging—Part II: treatment indications and complications 60
Imatinib dose escalation to achieve molecular responses in patients with chronic myeloid leukemia in late chronic phase 59
Reactivation of p53 mutants by p53 reactivation and induction of massive apoptosis in thyroid cancer cells 59
BRIT1/MCPH1 expression in chronic myeloid leukemia and its regulation of the G2/M checkpoint. 59
Biological effects of insulin and its analogs on cancer cells with different insulin family receptor expression 59
MONOCYTIC MYELOID DERIVED SUPPRESSOR CELLS (M-MDSC) AS PROGNOSTIC FACTOR IN DASATINIB TREATED PATIENTS WITH CHRONIC MYELOID LEUKEMIA 59
Insulin receptor isoforms in cancer 59
Influence of complex variant chromosomal translocations in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors 58
Basal insulin and cardiovascular and other outcomes 58
Increased phospho-mTOR expression in megakaryocytic cells derived from CD34+ progenitors of essential thrombocythaemia and myelofibrosis patients 58
Monocytic Myeloid Derived Suppressor CELLS (M-MDSC) As Prognostic Factor in Chronic Myeloid Leukemia Patients Treated with Dasatinib 58
Overexpression of membrane glycoprotein PC-1 in MDA-MB231 breast cancer cells is associated with inhibition of insulin receptor tyrosine kinase activity 58
Interplay between Kinase Domain Autophosphorylation and F-Actin Binding Domain in Regulating Imatinib Sensitivity and Nuclear Import of BCR-ABL 57
Espressione e funzione di OMI/HTRA2 in tumori solidi ed ematologici 57
Diabetes and cancer 56
BCR-ABLIS Expression at Diagnosis and After 3 or 6 Months of Treatment Predicts CML Response to IMATINIB Therapy 56
Prospective assessment of NGS-detectable mutations in CML patients with non-optimal response: the NEXT-in-CML study 56
Totale 7.261
Salva come PNG Salva come JPEG
Categoria #
all - tutte 53.175
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 53.175
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020179 0 0 0 0 0 0 0 0 0 0 102 77
2020/20211.259 16 92 141 15 306 36 136 6 235 4 185 87
2021/20221.503 156 203 22 20 230 37 224 49 137 28 56 341
2022/20232.778 229 144 58 296 208 463 32 541 633 20 94 60
2023/20241.448 108 220 52 79 76 257 34 86 10 67 272 187
2024/20254.722 163 871 312 258 1.154 689 255 186 365 463 6 0
Totale 13.151